FDA Should Resolve Patent Dispute In AmCell Case, Delaware Court Rules
This article was originally published in The Gray Sheet
Executive Summary
FDA should clarify whether an exemption in U.S. patent law protects AmCell Corp. from a patent infringement suit by Nexell Therapeutics, according to a summary judgment by the federal district court in Wilmington, Delaware.
You may also be interested in...
Nexell Sues Sublicensee Miltenyi In Defense Of Stem Cell Purification Patents
Nexell Therapeutics' second move to defend patents covering the firm's proprietary stem cell purification technology kicked off with the recent filing of a patent suit in Delaware federal court.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.